Cargando…
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signalin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604914/ https://www.ncbi.nlm.nih.gov/pubmed/36294458 http://dx.doi.org/10.3390/jcm11206139 |
_version_ | 1784817934947844096 |
---|---|
author | Garg, Neeta Padron, Elizabeth Jordan Rammohan, Kottil W. Goodman, Courtney Frances |
author_facet | Garg, Neeta Padron, Elizabeth Jordan Rammohan, Kottil W. Goodman, Courtney Frances |
author_sort | Garg, Neeta |
collection | PubMed |
description | Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders. |
format | Online Article Text |
id | pubmed-9604914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96049142022-10-27 Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis Garg, Neeta Padron, Elizabeth Jordan Rammohan, Kottil W. Goodman, Courtney Frances J Clin Med Review Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders. MDPI 2022-10-18 /pmc/articles/PMC9604914/ /pubmed/36294458 http://dx.doi.org/10.3390/jcm11206139 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Garg, Neeta Padron, Elizabeth Jordan Rammohan, Kottil W. Goodman, Courtney Frances Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title | Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title_full | Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title_fullStr | Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title_full_unstemmed | Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title_short | Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis |
title_sort | bruton’s tyrosine kinase inhibitors: the next frontier of b-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604914/ https://www.ncbi.nlm.nih.gov/pubmed/36294458 http://dx.doi.org/10.3390/jcm11206139 |
work_keys_str_mv | AT gargneeta brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis AT padronelizabethjordan brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis AT rammohankottilw brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis AT goodmancourtneyfrances brutonstyrosinekinaseinhibitorsthenextfrontierofbcelltargetedtherapiesforcancerautoimmunedisordersandmultiplesclerosis |